MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alto Neuroscience, Inc. Common Stock (NY:ANRO)

21.65 -1.33 (-5.79%)
Streaming Delayed Price Updated: 3:21 PM EDT, May 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 568,968
Open 22.70
Bid (Size) 21.55 (100)
Ask (Size) 21.75 (400)
Prev. Close 22.98
Today's Range 21.20 - 23.25
52wk Range 2.150 - 28.44
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Alto Neuroscience CEO Amit Etkin, M.D., Ph.D. Receives Columbia University Transformational Research Award
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Reports First Quarter 2026 Financial Results and Recent Business Highlights
From Alto Neuroscience, Inc.
Via Business Wire

Performance

YTD
+30.5%
+30.5%
1 Month
-21.9%
-21.9%
3 Month
+12.4%
+12.4%
6 Month
+56.9%
+56.9%
1 Year
+752.4%
+752.4%

More News

Read More
News headline image
Alto Neuroscience Announces Participation in Upcoming Investor Conferences
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Presents Phase 2a Data for ALTO-207 in Major Depressive Disorder at SOBP Annual Meeting
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Reports Topline Data from Phase 2 Proof-of-Concept Study of ALTO-101 and Highlights Pipeline Advancements
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Announces $120 Million Private Placement Financing
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Announces Participation at the Stifel 2026 Virtual CNS Forum
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Announces Participation in Upcoming Investor Conferences
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Announces Completion of Enrollment in Phase 2 Proof-of-Concept Study of ALTO-101 in Cognitive Impairment Associated with Schizophrenia
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment
From Alto Neuroscience, Inc.
Via Business Wire
A Whole Watchlist of “Coiled Springs” (Found With One Simple ChartMill Screen) ↗
Via Chartmill
News headline image
Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Presents New Data at the 64th Annual Meeting of the American College of Neuropsychopharmacology
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Via Chartmill
News headline image
Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday ↗
Via Benzinga
News headline image
This Alto Neuroscience Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
Via Benzinga
News headline image
Alto Neuroscience Inc (NYSE:ANRO) Reports Narrower Q3 2025 Loss and Accelerated Pipeline Progress ↗
Via Chartmill
News headline image
Alto Neuroscience Reports Third Quarter 2025 Financial Results and Recent Business Highlights
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience to Participate in Upcoming Investor Conferences
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
These stocks are moving in today's session ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
Via Benzinga
News headline image
Top movers analysis in the middle of the day on 2025-10-20: top gainers and losers in today's session. ↗
Via Chartmill

Frequently Asked Questions

Is Alto Neuroscience, Inc. Common Stock publicly traded?
Yes, Alto Neuroscience, Inc. Common Stock is publicly traded.
What exchange does Alto Neuroscience, Inc. Common Stock trade on?
Alto Neuroscience, Inc. Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Alto Neuroscience, Inc. Common Stock?
The ticker symbol for Alto Neuroscience, Inc. Common Stock is ANRO on the New York Stock Exchange
What is the current price of Alto Neuroscience, Inc. Common Stock?
The current price of Alto Neuroscience, Inc. Common Stock is 21.65
When was Alto Neuroscience, Inc. Common Stock last traded?
The last trade of Alto Neuroscience, Inc. Common Stock was at 05/18/26 03:21 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story